Abstract：
This study arises from the need to understand the different therapies for cutaneous squamous cell carcinoma (SCC), especially in challenging clinical situations where conventional therapeutic options may not be optimal. The purpose of the study is to assess the efficacy and safety of intralesional methotrexate (MTX) as neoadjuvant therapy in the treatment of periocular SCC. The outcome of a patient after two separate intralesional MTX infiltrations 2 weeks apart is described. Therapeutic response was evaluated, achieving a significant reduction in tumor size and subsequently performing surgical excision of the residual lesion. The procedure was well tolerated, with no local or distant recurrences in the follow up. Intralesional MTX may be an effective and safe option in the neoadjuvant treatment of periocular SCC. Furthermore, we highlight the growing importance of immunotherapy in the approach to SCC and the need to familiarize specialists with these new treatments.
摘要：
这项研究源于需要了解皮肤鳞状细胞癌（SCC）的不同疗法，特别是在具有挑战性的临床情况下，传统的治疗选择可能不是最佳的。该研究的目的是评估甲氨蝶呤（MTX）作为新辅助疗法治疗眼周SCC的疗效和安全性。描述了间隔2周的两次单独的病灶内MTX浸润后的患者结果。评估治疗反应，实现肿瘤大小的显着减少，随后进行手术切除的残余病变。该程序耐受性良好，随访中没有局部或远处复发。病灶内MTX可能是新辅助治疗眼周SCC的有效和安全的选择。此外，我们强调了免疫治疗在SCC治疗方法中的重要性日益增加,以及需要让专家熟悉这些新疗法.
